A review of AbobotulinumtoxinA (Dysport).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journalArticle

10 Scopus citations


AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Issue number1 Suppl
StatePublished - Mar 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A review of AbobotulinumtoxinA (Dysport).'. Together they form a unique fingerprint.

  • Cite this

    Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., Sykes, J. M., & Waldorf, H. A. (2013). A review of AbobotulinumtoxinA (Dysport). Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, 33(1 Suppl). https://doi.org/10.1177/1090820X12474632